Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial
The combination of bevacizumab and erlotinib as switch maintenance improves progression-free survival with an acceptable safety profile compared with active surveillance in patients with advanced BTCs in this phase II study. The trial moves on to the phase III component to evaluate improvement in overall survival.
Authors
- Deepali Naughane
- Rajshree Patil
- Prabhat Bhargava (ORCID: https://orcid.org/0000-0002-6440-2186)
- Manali Parulekar
- Akhil Kapoor (ORCID: https://orcid.org/0000-0001-6006-2631)
- Anuprita Daddi
- Anant Ramaswamy (ORCID: https://orcid.org/0000-0002-8169-4264)
- Vikas Ostwal (ORCID: https://orcid.org/0000-0002-0067-4748)
- Deepali Chaugule
- Chaitali Nashikkar (ORCID: https://orcid.org/0000-0003-0052-3576)
- Sarika Mandavkar
- Bal Krishna Mishra (ORCID: https://orcid.org/0009-0007-1838-7097)
- S. Srinivas (ORCID: https://orcid.org/0000-0001-9981-364X)
- Suman Kumar Ankathi (ORCID: https://orcid.org/0000-0001-9756-1688)
- Neha Mer
- Rajiv Kumar (ORCID: https://orcid.org/0000-0003-0363-3287)
- Anuj Gupta (ORCID: https://orcid.org/0000-0001-7010-2836)
- Sadhana Kannan
- Nitin Shetty
Institutions
- Homi Bhabha National Institute (IN)
- Bhabha Hospital (IN)
- Tata Memorial Hospital (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1200/jco.23.02420
- Citations
- 2
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.15